4XB Stock Overview
A biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
XBiotech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.00 |
| 52 Week High | US$9.05 |
| 52 Week Low | US$3.14 |
| Beta | 1.41 |
| 11 Month Change | -26.47% |
| 3 Month Change | -35.48% |
| 1 Year Change | -0.99% |
| 33 Year Change | -62.38% |
| 5 Year Change | -28.06% |
| Change since IPO | -77.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4XB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 22.5% | -2.1% | -0.5% |
| 1Y | -1.0% | -19.2% | 1.6% |
Return vs Industry: 4XB exceeded the German Biotechs industry which returned -18.5% over the past year.
Return vs Market: 4XB underperformed the German Market which returned 2.4% over the past year.
Price Volatility
| 4XB volatility | |
|---|---|
| 4XB Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.5% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: 4XB's share price has been volatile over the past 3 months.
Volatility Over Time: 4XB's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 92 | John Simard | www.xbiotech.com |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
XBiotech Inc. Fundamentals Summary
| 4XB fundamental statistics | |
|---|---|
| Market cap | €157.31m |
| Earnings (TTM) | -€28.61m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.6x
P/E RatioIs 4XB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4XB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$30.74m |
| Earnings | -US$30.74m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.01 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 4.8% |
How did 4XB perform over the long term?
See historical performance and comparison